Atezolizumab

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Product Specifications

CAS Number

[1380723-44-3]

Product Name Alternative

MPDL3280A; RG-7446; RO-5541267

UNSPSC

12352203

Target

Apoptosis; Autophagy; PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Autophagy; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Anti-PD-L1_Neutralizing_Antibody.html

Purity

99.9

Solubility

H2O

Smiles

[Atezolizumab]

Molecular Weight

(144.6 kDa)

References & Citations

[1]Cha E, et al. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 2015 Jun;42 (3) :484-7.|[2]Liu Z, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12 (2) :164. Published 2021 Feb 8.